Valtecne (VLT) H2 2025 earnings summary

Executive summary

• FY 2025 revenues declined by 3.3% year-over-year to €35.7M, while value of production increased by 2.0% to €37.3M, driven by growth in the medical segment and continued weakness in industrial lines.

• Medical devices now represent 73% of total revenues, reflecting a strategic shift in the business mix.

• Net income dropped 31% to €3.3M, mainly due to goodwill amortization from the Utilità acquisition.

• Net financial position improved to €-1.8M (cash positive), reflecting strong operating cash generation.

• Board proposes a dividend of €0.10 per share, totaling €0.6M.

Financial highlights

• Adjusted EBITDA was €9.7M (26.0% of VoP), down 4.4% year-over-year; reported EBITDA was €8.1M (21.7% of VoP), down 4.1%.

• EBIT fell to €4.8M (12.8% of VoP) from €6.2M (17.1% of VoP) in FY 2024 pf.

• Shareholders' equity rose 4.8% to €27.1M.

• Net financial debt improved from €0.5M to €-1.8M (cash positive).

• Free cash flow remained solid, supported by operating performance.

Outlook and guidance

• Management expects robust revenue growth in FY 2026, led by the medical line and supported by favorable orthopedic industry trends (+4.2% expected growth in 2026).

• Dental and industrial sectors are projected to grow, with aerospace at all-time highs.

• Inflationary pressures from raw materials and energy are expected to have a limited impact on FY 2026 results.

• Operating profitability is anticipated to remain in line with recent years, despite higher costs from leadership team expansion.

• Industrial segment shows signs of demand recovery, especially in aerospace, but cost volatility remains a concern.